|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fessler E and Medema JP: Colorectal cancer
subtypes: Developmental origin and microenvironmental regulation.
Trends Cancer. 2:505–518. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shia J, Schultz N, Kuk D, Vakiani E,
Middha S, Segal NH, Hechtman JF, Berger MF, Stadler ZK, Weiser MR,
et al: Morphological characterization of colorectal cancers in The
Cancer Genome Atlas reveals distinct morphology-molecular
associations: Clinical and biological implications. Mod Pathol.
30:599–609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gibson TB, Ranganathan A and Grothey A:
Randomized phase III trial results of panitumumab, a fully human
anti-epidermal growth factor receptor monoclonal antibody, in
metastatic colorectal cancer. Clin Colorectal Cancer. 6:29–31.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Los M, Roodhart JML and Voest EE: Target
practice: Lessons from phase III trials with bevacizumab and
vatalanib in the treatment of advanced colorectal cancer.
Oncologist. 12:443–450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thom CS, Traxler EA, Khandros E, Nickas
JM, Zhou OY, Lazarus JE, Silva AP, Prabhu D, Yao Y, Aribeana C, et
al: Trim58 degrades Dynein and regulates terminal erythropoiesis.
Dev Cell. 30:688–700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qiu X, Huang Y, Zhou Y and Zheng F:
Aberrant methylation of TRIM58 in hepatocellular carcinoma and its
potential clinical implication. Oncol Rep. 36:811–818. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kajiura K, Masuda K, Naruto T, Kohmoto T,
Watabnabe M, Tsuboi M, Takizawa H, Kondo K, Tangoku A and Imoto I:
Frequent silencing of the candidate tumor suppressor TRIM58 by
promoter methylation in early-stage lung adenocarcinoma.
Oncotarget. 8:2890–2905. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dufour A and Overall CM: Missing the
target: Matrix metalloproteinase antitargets in inflammation and
cancer. Trends Pharmacol Sci. 34:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meroni G and Diez-Roux G: TRIM/RBCC, a
novel class of ‘single protein RING finger’ E3 ubiquitin ligases.
BioEssays. 27:1147–1157. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Elabd S, Meroni G and Blattner C: TRIMming
p53's anticancer activity. Oncogene. 35:5577–5584. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo P, Ma X, Zhao W, Huai W, Li T, Qiu Y,
Zhang Y and Han L: TRIM31 is upregulated in hepatocellular
carcinoma and promotes disease progression by inducing
ubiquitination of TSC1-TSC2 complex. Oncogene. 37:478–488. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawabata H, Azuma K, Ikeda K, Sugitani I,
Kinowaki K, Fujii T, Osaki A, Saeki T, Horie-Inoue K and Inoue S:
TRIM44 is a poor prognostic factor for breast cancer patients as a
modulator of NF-κB signaling. Int J Mol Sci. 18:E19312017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu G, Guo Y, Xu D, Wang Y, Shen Y, Wang F,
Lv Y, Song F, Jiang D, Zhang Y, et al: TRIM14 regulates cell
proliferation and invasion in osteosarcoma via promotion of the AKT
signaling pathway. Sci Rep. 7:424112017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horn EJ, Albor A, Liu Y, El-Hizawi S,
Vanderbeek GE, Babcock M, Bowden GT, Hennings H, Lozano G, Weinberg
WC, et al: RING protein Trim32 associated with skin carcinogenesis
has anti-apoptotic and E3-ubiquitin ligase properties.
Carcinogenesis. 25:157–167. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zehir A, Benayed R, Shah RH, Syed A,
Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, et
al: Mutational landscape of metastatic cancer revealed from
prospective clinical sequencing of 10,000 patients. Nat Med.
23:703–713. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hause RJ, Pritchard CC, Shendure J and
Salipante SJ: Classification and characterization of microsatellite
instability across 18 cancer types. Nat Med. 22:1342–1350. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Friedl P and Alexander S: Cancer invasion
and the microenvironment: Plasticity and reciprocity. Cell.
147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
|
